These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 3521847

  • 1. Trial of high-dose cytarabine, cyclophosphamide, total-body irradiation, and autologous marrow transplantation for refractory lymphoma.
    Armitage JO, Gingrich RD, Klassen LW, Bierman PJ, Kumar PP, Weisenburger DD, Smith DM.
    Cancer Treat Rep; 1986 Jul; 70(7):871-5. PubMed ID: 3521847
    [Abstract] [Full Text] [Related]

  • 2. Treatment of refractory lymphoma with high dose cytarabine, cyclophosphamide and either TBI or VP-16 followed by autologous bone marrow transplantation.
    Broun ER, Tricot G, Akard L, Nichols C, Cheerva A, Jansen J.
    Bone Marrow Transplant; 1990 May; 5(5):341-4. PubMed ID: 2190660
    [Abstract] [Full Text] [Related]

  • 3. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [Abstract] [Full Text] [Related]

  • 4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation.
    Geller RB, Myers S, Devine S, Larson RA, Williams SF, Park CL, O'Toole K, Chandler C, Topper RL.
    Bone Marrow Transplant; 1992 Jan; 9(1):41-7. PubMed ID: 1543948
    [Abstract] [Full Text] [Related]

  • 6. Involved field radiation, fractionated total body irradiation, high dose cyclophosphamide, and autologous bone marrow transplantation in the treatment of malignant lymphomas.
    Ghalie R, Richman CM, Adler SS, Korenblit AD, Kramer TS, Manson S, Dolce A, Kaizer H.
    Bone Marrow Transplant; 1991 Jul; 8(1):41-5. PubMed ID: 1912954
    [Abstract] [Full Text] [Related]

  • 7. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR, Mangan KF, Glenn LD, Malaspina DR, Cropper T, Mullaney M, Macdonald JS.
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [Abstract] [Full Text] [Related]

  • 8. Prolonged disease-free survival after ablative chemoradiotherapy and autologous bone marrow transplantation in adult malignant lymphoma.
    Da WM, Zhong JT, Liu Y, Huang YS, Bai H, Wu XX, Ou YX, Wang CB, Xu SF.
    Chin Med J (Engl); 1993 Apr; 106(4):277-81. PubMed ID: 8325155
    [Abstract] [Full Text] [Related]

  • 9. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
    Snyder MJ, Johnson DB, Daly MB, Giguere JK, Harman GH, Harden EA, Johnson RA, Leff RS, Mercier RJ, Messerschmidt GL.
    Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534
    [Abstract] [Full Text] [Related]

  • 10. Intensive therapy and autotransplantation in Hodgkin's disease.
    Reece DE, Phillips GL.
    Stem Cells; 1994 Sep; 12(5):477-93. PubMed ID: 7804123
    [Abstract] [Full Text] [Related]

  • 11. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
    van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I.
    Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
    [Abstract] [Full Text] [Related]

  • 12. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ, Taylor PR, Angus B, Wood K, Lennard AL, Lucraft H, Carey PJ, Stark A, Iqbal A, Haynes A, Russel N, Leonard RC, Culligan D, Conn J, Jackson GH.
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [Abstract] [Full Text] [Related]

  • 13. [High-dosage chemo-radiotherapy with autologous bone marrow transfusion in malignant lymphoma: indications and personal experience].
    Stahel RA, Jost LM, Burger J, Honegger HP, Brun del Re GP, Gmür J.
    Schweiz Med Wochenschr; 1989 Jun 24; 119(25):911-7. PubMed ID: 2667131
    [Abstract] [Full Text] [Related]

  • 14. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E.
    Haematologica; 2000 Mar 24; 85(3):263-8. PubMed ID: 10702814
    [Abstract] [Full Text] [Related]

  • 15. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC, Canales MA, Ojeda E, de Bustos JG, Aguado MJ, Hernández-Navarro F.
    Haematologica; 1999 Nov 24; 84(11):1007-11. PubMed ID: 10553161
    [Abstract] [Full Text] [Related]

  • 16. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R, Moos M, Möhle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W.
    Bone Marrow Transplant; 1996 Feb 24; 17(2):149-55. PubMed ID: 8640159
    [Abstract] [Full Text] [Related]

  • 17. Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow.
    Phillips GL, Herzig RH, Lazarus HM, Fay JW, Wolff SN, Mill WB, Lin H, Thomas PR, Glasgow GP, Shina DC.
    N Engl J Med; 1984 Jun 14; 310(24):1557-61. PubMed ID: 6374452
    [Abstract] [Full Text] [Related]

  • 18. High-dose sequential (HDS) chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma.
    Caracciolo D, Gavarotti P, Aglietta M, Bondesan P, Falda M, Gallo E, Locatelli F, Novarino A, Paolino F, Sanavio F.
    Bone Marrow Transplant; 1993 Dec 14; 12(6):621-5. PubMed ID: 7907906
    [Abstract] [Full Text] [Related]

  • 19. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
    Schiffman K, Buckner CD, Maziarz R, Maloney DG, Appelbaum FR, Press O, Gooley T, Holmberg L, Lilleby K, Clift R, Zuckerman N, Klarnet J, Weaver C, Chauncey T, Bensinger WI.
    Biol Blood Marrow Transplant; 1997 Nov 14; 3(5):261-6. PubMed ID: 9450921
    [Abstract] [Full Text] [Related]

  • 20. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.
    Kröger N, Hoffknecht M, Hänel M, Krüger W, Zeller W, Stockschläder M, de Wit M, Weh HJ, Kabisch H, Erttmann R, Zander AR.
    Bone Marrow Transplant; 1998 Jun 14; 21(12):1171-5. PubMed ID: 9674847
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.